Vanguard Capital Management
NRIX icon

Vanguard Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Vanguard Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109M Buy
4,495,529
+68,417
+2% +$1.17M ﹤0.01% 1517
2026
Q1 		$68.6M Buy
+4,427,112
New +$73.4M ﹤0.01% 1677

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management's NRIX Position: Q2 2026 in Review

Vanguard Capital Management increased its Nurix Therapeutics (NRIX) stake by 1.5% in Q2 2026, buying an estimated $1.17M and bringing the position to 4,495,529 shares worth $109M. The position accounts for ﹤0.01% of the portfolio, ranked #1517.

Vanguard Capital Management first reported a position in NRIX in Q1 2026 and has held it in 2 quarters since. 210 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Vanguard Capital Management held 4,495,529 shares of Nurix Therapeutics worth $109M as of Q2 2026.
  • Vanguard Capital Management bought 68,417 Nurix Therapeutics shares in Q2 2026, an estimated $1.17M.
  • Nurix Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1517 holding.
  • Vanguard Capital Management first reported a position in Nurix Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 210 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.